Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) ...

The FDA approved Opdualag on the strength of the ... BMS' notoriously hard to tolerate CTLA4 checkpoint inhibitor – which has been approved as a monotherapy for melanoma since 2011 and as ...

Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in ... approval of Optune Lua by the U.S. Food and Drug Administration in October 2024.

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category ... or labelling issues with the drug, and Checkpoint has said it hopes to re-apply for approval swiftly.

Q1 2025 Earnings Call Transcript April 24, 2025 NovoCure Limited beats earnings expectations. Reported EPS is $-0.31, ...

Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. | Paul Reider has followed Coherus ...